Project-COMFORT Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)
- Coordinator
- Aristotelio Panepistimio Thessalonikis, Greece
- Runs
- 1 November 2024 to 30 April 2028
- Status
- Running
- EU funding
- €3.0m
- Total cost
- €6.7m
- Partners
- 56 organisations in 13 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101163781
What the project is doing
In the project's own words, from its summary on CORDIS.
BackgroundHealth systems face a time of unprecedented change, with spiraling costs, increasing cultural disparity in access to healthcare and research, and an infrastructure that is decades old. Today, telehealth is a realistic alternative making care and research more accessible and personalised with less burden to better support the most vulnerable and under-served in our society. The ability to test and monitor for illnesses using Patient Centric micro-Sampling (PCmS) is at the centre of this reform.
Aim and main objectivesThis project is designed to build upon existing pilots and knowledge, then collaborate cross-sectorially to co-create and test the logistics, infrastructure and tools required to make PCmS a core healthcare tool and an acceptable alternative to venous blood-draw across Europe. This project aligns with many IHI’s objectives focusing on cross-sectorial collaboration, emphasizing patient and end-user- centric co-design of outputs, harmonised regulatory and data generation approaches enhancing the potential of digital innovations in healthcare, while aiming to reduce the environmental footprint during the project and in final outputs to ensure that the expected long-term impact is a reachable reality that will deliver significant benefit to the community and address unmet public health needs at scale.
To achieve our objectives, we bring together a broad group of required expertise, know-how and end-users (i.e., public and patients) to form a public-private-partnership specifically equipped to tackle this challenge. This collaborative approach where the relevant stakeholders such as healthcare professionals, regulatory agencies and patients are involved and integrated to deliver solutions and innovation across healthcare systems and ensure the best chances for success and long-term positive impact from this project.
Key deliverables include:1)An optimized, tested and validated ‘Gold Standard’ infrastructure and workflow for PCmS across Europe as a proven and reliable alternative to venipuncture2)Harmonised and clear regulatory and HTA pathways, standards and acceptability, measures and cost-benefit models across Europe3)Documented evidence to draw a citable ‘line in the sand’ for future research to support decisions to integrate PCmS into decentralised trials and care pathways4)Stakeholder engagement and patient involvement models and research on preferences and acceptability for PCmS5)Foundation for future: Enable access to the developed PCmS scientific findings, tools and assessment measures for rapid uptake and integration of PCmS approaches into decentralised clinical studies and healthcareExpected impact:-Patient-centric microsampling becomes an accepted alternative to the current standard of care venipuncture and the data gathered can be leveraged in healthcare planning.-Lowered patient burden and lowered barrier to access in situations where blood samples need to be collected, whether as part of diagnosis, care plan, health monitoring etc. -A solution to leverage high amounts of data gathered from increased testing can be explored already in this project so that it can pave the way for future research that can improve health outcomes.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Aristotelio Panepistimio Thessalonikis | Thessaloniki | Greece | Coordinator |
| European Centre for Clinical Research Training | Bruxelles / Brussel | Belgium | Participant |
| Glaxosmithkline Biologicals SA | Rixensart | Belgium | Associatedpartner |
| Iqvia Solutions Belgium | Zaventem | Belgium | Participant |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Roche Diagnostics International AG | Rotkreuz | Switzerland | Associatedpartner |
| Univerzita Palackeho V Olomouci | Olomouc | Czechia | Participant |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Jones Lang Lasalle Se | Frankfurt Am Main | Germany | Participant |
| Lilly Deutschland GmbH | Bad Homburg | Germany | Associatedpartner |
| Miebach Consulting GmbH | Frankfurt Am Main | Germany | Participant |
| Siemens Healthineers AG | Forchheim | Germany | Participant |
| Collaborate Healthcare- Kainotomes Ypiresies Ygeias Ike | Paiania Attiki | Greece | Participant |
| Thetabiomarkers Ike | Thessaloniki | Greece | Participant |
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Participant |
| Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I Gurina | Barcelona | Spain | Participant |
| Fundacio Privada per a La Recerca I La Docencia Sant Joan De Deu | Esplugues De Llobregat | Spain | Participant |
| Fundacion Para La Investigacion De Malaga En Biomedicina Y Salud | Malaga | Spain | Participant |
| Hospital Sant Joan De Deu | Esplugues De Llobregat | Spain | Third party |
| Institut Catala De La Salut | Barcelona | Spain | Third party |
| Servicio Andaluz De Salud | Sevilla | Spain | Third party |
| Becton Dickinson France SAS | Le Pont De Claix | France | Participant |
| Euraxi Pharma | Joue les Tours | France | Participant |
| Institut De Recherches Internationales Servier | Gif-Sur-Yvette | France | Participant |
| Institut Pasteur | Paris | France | Participant |
| Institut Servier D'innovation Therapeutique | Gif-Sur-Yvette | France | Associatedpartner |
| Technologie Servier | Orleans | France | Associatedpartner |
| Eli Lilly Kinsale Ltd | Cork | Ireland | Associatedpartner |
| Bayer SpA | Milan | Italy | Associatedpartner |
| Pharma Quality Europe SRL | Reggello | Italy | Participant |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Stichting Sanquin Bloedvoorziening | Amsterdam | Netherlands | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Participant |
| Capitainer AB | Solna | Sweden | Participant |
| International Doping Tests Management AB Idtm | Stockholm | Sweden | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Region Stockholm | Stockholm | Sweden | Participant |
| Bayer Public Limited Company | Newbury | United Kingdom | Associatedpartner |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Participant |
| Labcorp Early Development Laboratories Limited | Harrogate | United Kingdom | Participant |
| Medipace Limited | London | United Kingdom | Associatedpartner |
| Patient Centric Sampling Interest Group Cic | Ware | United Kingdom | Associatedpartner |
| Pfizer Limited | Sandwich | United Kingdom | Associatedpartner |
| Pfizer R&D UK Limited | Sandwich | United Kingdom | Associatedpartner |
| Trajan Scientific Europe Ltd | Milton Keynes | United Kingdom | Associatedpartner |
| University of Dundee | Dundee | United Kingdom | Associatedpartner |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Associatedpartner |
| Abbvie Inc | North Chicago Il | United States | Participant |
| Eli Lilly and Company | Indianapolis | United States | Participant |
| Pfizer Inc | New York City | United States | Participant |
| Q Squared Solutions LLC | Raleigh | United States | Associatedpartner |
| Rhinostics, Inc. | Waltham | United States | Associatedpartner |
| Tasso Inc | Seattle | United States | Associatedpartner |
| YourBio Health, Inc. | Medford, MA | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI